CBD drug Epidyolex looks unlikely to get a NICE answer in the UK

The panel largely responsible for recommending which drugs the UK’s National Health Service (NHS) should provide may discourage use of the CBD-based drug Epidyolex ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Pablo Sharrock
+34 722 642 678
Email Pablo